Latest Breaking News On - Reponex pharmaceuticalsas - Page 1 : comparemela.com

Consolidated interim report 1 January – 31 March 2024

Consolidated interim report 1 January – 31 March 2024
marketscreener.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from marketscreener.com Daily Mail and Mail on Sunday newspapers.

Distrito de setubalUnited kingdomReponex pharmaceuticalsHigh courtDanske bankCompany announcementEuropean patent officeCompany announcement noReponex pharmaceuticalsasPharma equity groupCompany danishCompany announcementsBoard of directors the companyCompany portugueseManagement of pharma equity groupExecutive management

Pharma Equity A/S : 2024 Q1 Consolidated Interim Report

Consolidated interim report for the 3 month-period ended 31 March 2024 Pharma Equity Group A/S Slotsmarken 18, 2.,.

Distrito de setubalTroels peter troelsenMartin engell rossenPeter vilmannLars rosenkrantz gundorphCharlotte pahlOmars qandeelBoard of directors the companyReponex pharmaceuticalsasBiopharma holding apCompany portugueseDanske bankEuropean patent officeCompany danishStock exchangeCompany announcement no

Pharma Equity Group s subsidiary, Reponex Pharmaceuticals A/S, reports highly positive final results from the phase-2 clinical trial of the company s patented drug candidate RNX-051 | 05 04 24

Pharma Equity Group s subsidiary, Reponex Pharmaceuticals A/S, reports highly positive final results from the phase-2 clinical trial of the company s patented drug candidate RNX-051 | 05 04 24
finanzen.ch - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanzen.ch Daily Mail and Mail on Sunday newspapers.

Company announcement noReponex pharmaceuticalsPharma equity groupReponex pharmaceuticalsasEquity groupKaas selsNasdaq copenhagenReponex pharmaceutical

Pharma Equity Group s subsidiary, Reponex Pharmaceuticals A/S, reports highly positive final results from the phase-2 clinical trial of the company s patented drug candidate RNX-051 -April 05, 2024 at 05:23 am EDT

5 April 2024 Company Announcement No. 11 Pharma Equity Group’s subsidiary, Reponex Pharmaceuticals A/S, reports highly positive final results from the phase-2 clinical trial of the company’s.

United kingdomPharma equity groupCompany announcement noReponex pharmaceuticalsasReponex pharmaceuticalsEquity groupKaas selsNasdaq copenhagenReponex pharmaceutical

Pharma Equity A/S : Group s subsidiary, Reponex Pharmaceuticals A/S, reports highly positive final results from the phase-2 clinical trial of the company s patented drug candidate RNX-051 -April 05, 2024 at 05:29 am EDT

Danish English .

United kingdomReponex pharmaceuticalsReponex pharmaceuticalsasCompany announcement noPharma equity groupEquity groupKaas selsNasdaq copenhagenReponex pharmaceutical